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Abstract
Squalene, an isoprenoid antioxidant is a potential cytoprotective agent against chemotherapy-induced toxicity. We
have previously published that squalene protects light-density bone marrow cells against cis-diamminedichloropla-
tinum(II) (cisplatin)–induced toxicity without protecting tumor cells in vitro. Here, we developed an in vivo mouse
model of cisplatin and cis-diammine (cyclobutane-1,1-dicarboxylato) platinum(II) (carboplatin)–induced toxicity to
further investigate squalene-mediated LD-BM cytoprotection including the molecular mechanism behind selective
cytoprotection. We found that squalene significantly reduced the body weight loss of cisplatin and carboplatin–
treated mice. Light-density bone marrow cells from squalene-treated mice exhibited improved formation of hemato-
poietic colonies (colony-forming unit–granulocyte macrophage). Furthermore, squalene also protected mesenchymal
stem cell colonies (colony-forming unit–fibroblast) from cisplatin and carboplatin–induced toxicity. Squalene-induced
protectionwas associatedwith decreased reactive oxygen species and increased levels of glutathione and glutathione
peroxidase/glutathione-S -transferase. Importantly, squalene did not protect neuroblastoma, small cell carcinoma, or
medulloblastoma xenografts against cisplatin-induced toxicity. These results suggest that squalene is a potential can-
didate for future development as a cytoprotective agent against chemotherapeutic toxicity.
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Introduction
Myelosuppression is a major toxicity for most chemotherapy regi-
mens. Myelotoxicity is associated with morbidity, mortality, cost,
and, most importantly, with reduced chemotherapy dose intensity
and treatment failure [1,2]. The reduction in dose intensity may com-
promise treatment outcome including disease control and survival
in patients with curable malignancies [1]. Among the most com-
monly used myelosuppressive drugs are the platinum derivatives cis-
diammine (cyclobutane-1,1-dicarboxylato) platinum(II) (carboplatin)
and cis-diamminedichloroplatinum(II) (cisplatin) [3]. Carboplatin is
a second-generation platinum complex having substantial myelosup-
pressive effects. The toxicity is cumulative in nature and can occur in
18% to 25% of cases [3]. Treatment with high-dose carboplatin
(>1200 mg/m2) leads to myelosuppression in >90% of cases [4]. Cis-
platin is the first generation platinum compound having mild myelo-
suppressive effects (5-6% cases). The toxicity is correlated with peak
levels of the drug in the first 2 weeks of treatment [4,5], and its inci-
dence and severity dramatically increase in patients under dialysis
(25-100% cases) [5,6] and when used in combination with carbo-
platin [7].
One of the known mechanisms of toxicity of platinum drugs such
as cisplatin and carboplatin is due to cross-linking with nucleic acids
and proteins. Both cisplatin and carboplatin are platinum(II) com-
plexes with two ammonia groups in the cis position. Cisplatin has
two chloride groups, which are replaced by water molecules in an in-
tracellular aquation reaction. The reaction is driven by the high con-
centration of water and low concentration of chloride in the tissues.
The aquated platinum complex can then react with a variety of mac-
romolecules including RNA, DNA, and protein. The cytotoxicity of
cisplatin is correlated closely with platinum DNA interstrand bifunc-
tional N-7 adducts at d(GpG) and d(Apg) [8]. However, so far, the
types of DNA lesions responsible for the cytotoxicity of cisplatin have
not been clearly established [3]. Other toxic effects of cisplatin in vitro–
cultured cell growth includes attenuation of mitochondrial function
and the release of reactive oxygen species in the cells [9,10]. Carbo-
platin has a similar mechanism of action like cisplatin [3].
The mechanism of platinum-induced myelosuppression is not
clearly known. Evans et al. [11] reported that after a single dose of
cisplatin treatment (4-20 mg/kg) in hybrid mice (C57BL × BALB/c),
the light-density bone marrow (LD-BM)–derived colony-forming
units (CFUs) were depleted significantly. Nowrousian and Schmidt
[12] found similar results of the depletion of the CFUs suggesting
that cisplatin may target the hematopoietic stem cell fraction lead-
ing to myelosuppression. We previously reported that cisplatin treat-
ment exerts significant toxicity on the hematopoietic stem cell fraction
in vitro [13]. Carboplatin has also been found to target the hemato-
poietic stem cell fraction both in vitro and in vivo [3,14,15]. The
mechanism of platinum-induced toxicity on hematopoietic stem cells
may be related to its DNA cross-linking and generation of oxidative
stress products such as malondialdehyde [16]. Carboplatin may have
a similar mechanism of oxidative stress induction as cisplatin [3], and
it has been found to decrease glutathione (GSH) level in rat kidney
[17] and bone marrow (BM) cells [18]. Antioxidants GSH and me-
tallothioneins are found to prevent cisplatin and carboplatin–induced
toxicity [19–22]. Hence, the clinical use of antioxidants have been
suggested to reduce cisplatin and carboplatin–induced myelosup-
pression [21,23–28].
Squalene is an isoprenoid antioxidant that is secreted in human
sebum, where it may protect skin from UV radiation [29]. Dietary
squalene has been found to have radioprotective activity [30] and
exerts anticarcinogenic activity against several compounds by en-
hancing cellular antioxidant status [31–34]. Our in vitro studies in
squalene-mediated cytoprotection indicate that squalene (12.5-
25 μM) has selective cytoprotective activity; it protected BM colonies
from cisplatin-induced toxicity without protecting neuroblastoma
colonies [13]. Importantly, the cytoprotective activity of squalene
was equivalent to GSH, a major intracellular antioxidant and detox-
ifying agent [20]. Furthermore, squalene may have antitumor activ-
ity. It has been previously shown that squalene inhibited murine
sarcoma growth and survival in a mouse model [35–38]. We found
that squalene inhibits the in vitro growth of the NBL-S neuroblas-
toma cell line [13].
Such differential normal tissue protective, anticarcinogenic, and
antitumor activities make squalene a potential cytoprotective agent
against chemotherapeutic-induced myelotoxicity [13,29]. To test this
possibility, we investigated the in vivo protective activity of squalene
in a mouse model of platinum-induced myelotoxicity. We also inves-
tigated the potential protective activity of squalene against platinum-
induced toxicity against tumor growth in vivo.
Materials and Methods
Cell Culture
Fresh normal mouse BM specimens were obtained from mice;
normal LD-BM mononuclear cells (LD-BM cells) were separated
by the Percoll method as described [39]. Separated LD-BM cells were
immediately used for the CFU assay as described below. Tumor cell
lines, SK-N-BE(2) (a neuroblastoma cell line), H-146 (a small cell
carcinoma cell line), and D-283 (a medulloblastoma cell line), were
obtained from the American Type Culture Corporation (ATCC,
Manassas, VA) and maintained according to ATCC guidelines.
Reagents and Drugs
Cisplatin, carboplatin, and reduced GSH were obtained from
Sigma-Aldrich, Oakville, ON, Canada. Unless stated otherwise, tissue
culture and other reagents/drugs were obtained from Sigma-Aldrich.
Both cisplatin and carboplatin were dissolved in normal saline.
Squalene Preparation
Squalene (Squalene iP6, derived from dogfish shark oil) was a
gift from Isshogenki International, Hong Kong. Gas chromatog-
raphy analysis performed in our laboratory established the purity
of Squalene iP6 as more than 99.3% [13]. Squalene was mixed with
commercially available Intralipid 200-mg/ml fat emulsion to make
a 0.8-mg/ml solution of squalene in Intralipid as described [40].
The squalene-Intralipid solution was injected intraperitoneally (i.p.)
at 100 mg/kg (1 ml of 2-mg/ml squalene-Intralipid solution injected
i.p. into a 20-g BALB/c mouse).
Animals
Eight- to ten-week-old female BALB/c/nude/nude mice were
obtained from Charles River Laboratories (Wilmington, MA). Proto-
cols for animal experimentation were approved by the Animal Safety
Committee, Research Institute, The Hospital for Sick Children,
Toronto, Canada. The details are described in the Supplementary
Methods section.
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In Vivo Xenograft Assay
The neuroblastoma cell lines SK-N-BE(2), SH-SY5Y, small cell
carcinoma cell line H-146, and medulloblastoma cell line D-283
were used for the xenograft study. Briefly, trypan blue–excluded via-
ble cells (6 × 106) were mixed with Matrigel (50 μl of cell suspension
in 50 μl of Matrigel) and injected subcutaneously into both flanks
of female nude mice (BALB/c, nude/nude; n = 6). The tumor size
was measured with a caliper on a biweekly basis, and tumor volume
was determined using the formula 0.5ab2, where b is the smaller
of the two perpendicular diameters as described [41]. As required,
tumors were harvested, weighed, and then dissociated into cell suspen-
sions by a simple method of trituration (finely minced tumor tissue
transferred to a 15-ml tube and vigorously pipetted for 1-2 minutes).
The resulting cell suspensions were centrifuged and washed with PBS
twice and then trypsinized in 2 × trypsin EDTA solutions for 15 min-
utes. This suspension was washed and counted for viability using
the Trypan blue assay and was plated in methylcellulose medium for
clonogenic study. To study the long-term effect of squalene cytopro-
tection against tumor growth, 10-week-old BALB/c nude/nude mice
(weight, 19.3 g, 95% confidence interval, 19-19.7 g) were used. Group
1 mice were killed when the tumor reached 2 cm3 in size. At the ap-
propriate time, platinum drug was injected i.p. 3 hours after the in-
jection of squalene i.p., and tumor growth was monitored. Mice were
killed at the ninth week, and BM cells were isolated to perform the
CFUs and CFU-F assays. For the SH-SY5Y cell line, a separate protocol
was used as described in the text.
Measurement of BM Protection: CFU Assay
For the evaluation of BM toxicity, we used a method developed
by Treskes et al. [42], where LD-BM cells from the mouse BM were
isolated, and in vitro colony assay was performed. The assay was
performed using a standardized methylcellulose assay system [13] us-
ing Methocult GF H4434 (StemCell Technologies Inc., Vancouver,
BC, Canada) containing recombinant growth factors including
granulocyte colony-stimulating factor (CSF) and erythropoietin.
Briefly, normal LD-BM cells were immediately plated in methylcel-
lulose medium (Methocult GF H4434), and CFUs were counted af-
ter 14 days.
Measurement of Mesenchymal Stem Cell Protection:
CFU-F Assay
The assay was performed using the Mesencult medium (#05501
and #05502; StemCell Technologies) as per the manufacturer’s in-
struction. Briefly, total BM cells were collected from a mouse femur
(∼2 × 107 cells) into 2 ml of Iscove’s modified Dulbecco’s medium
supplemented with 2% FBS, and after cell counting, 1 × 106 cells
were plated per well in a six-well plate in 2 ml of Mesencult medium.
At day 14, colonies were fixed with methanol, stained with Giemsa,
and CFU-F (CFU-fibroblast) was counted [43]. Osteogenic and
adipogenic differentiation was performed as described [44]. Briefly,
BM cells were cultured to three to four passages in Mesencult me-
dia and then incubated in osteogenic and adipogenic medium for
3 weeks, and medium was changed every 72 hours. Osteogenic me-
dium contained DMEM, 10% FBS, 0.1 μMdexamethasone, 10 mM
glycerophosphate, and 5 μg/ml ascorbic acid. After 3 weeks, cultures
were washed with PBS, fixed with 10% formalin, and stained with
Alizarin red for calcium deposition and alkaline phosphatase activity.
The adipogenic medium was made of DMEM, 10% FBS, 0.1 μM
dexamethasone, and 5 μg/ml insulin. After 3 weeks, cultures were
fixed with 10% formalin and stained with oil red O stain.
Measurement of Cellular Proliferation and
Toxicity by Clonogenic Assay
The assay was performed as previously described [13,45]. A total of
2 × 103 tumor cells were seeded in methylcellulose medium (Metho-
cult M3134; StemCell Technologies) with 10% FBS with or without
treatment with cisplatin, and after 2 weeks of culture at 37°C and
5% CO2, colonies were counted as described [13].
Measurement of Antioxidant Enzymes
Superoxide dismutase (SOD), glutathione-S -transferase (GST),
and glutathione peroxidase (GSPx) were measured using standard
assay kits (Cayman Chemical Company, Ann Arbor, MI). For sample
preparation, a modified method was used where cell pellets were
homogenized in a common lysis buffer (50 mM Tris-HCl, pH
7.6, containing 5 mM EDTA and 1 mM DTT). Briefly, 2 × lysis
buffer was added, and samples were homogenized for 5 to 10 seconds
on ice and then stored at −80°C (stored for 3-6 months). Subse-
quently, samples were thawed, protein levels were measured, and
the samples diluted in a standard buffer (50 mM Tris-HCl, pH
7.6, 5 mM EDTA); these were pipetted into 96-well plates with
additional reagents provided in the kit to measure SOD, GST, and
GSPx level. The measurement was done by reading the change in
absorbance using a spectrophotometer according to the manufac-
turer’s instructions.
GSH Measurement
A GSH assay kit was obtained from Oxford Biomedical Research,
Oxford, MI. Murine BM cells or xenograft tissues were dissociated
using a lysis buffer containing 50 mM sodium phosphate, pH 6.7,
and 1 mM EDTA. A part of the lysate was used to measure protein
concentration by BCA protein assay kit (Pierce, Rockford, IL), and
100 μl of lysates were dissolved in an equal volume of 5% metaphos-
phoric acid. Glutathione was measured by a colorimetric-based
method using a methyl-sulfate reagent (Oxford Biomedical Research).
In the assay, GSH present in the lysate reacts with the methyl-sulfate
reagent to produce a GSH-thioether, which is converted to chromo-
phoric thione (absorbance, 400 nm) under alkaline conditions (pH >
13.4). A standard curve was obtained using known GSH concentra-
tions. Data were normalized per milligram of protein.
Measurement of Intracellular ROS
The intracellular level of ROS was measured with 2′,7′-dichloro-
fluorescein diacetate (DCFH-DA; Sigma-Aldrich) as described [46].
Briefly, BM and tumor cells were plated in a 96-well plate (4 × 104
per well) and preincubated with DCFH-DA dye, and the relative
fluorescence unit was obtained after 30 minutes in a Gemini Spectra
MAX microplate reader (Molecular Devices, Sunnyvale, CA).
Measurement of Tissue Squalene
Spanggord et al. [47] described a hexane-based extraction method
to measure squalene, where a reverse-phase HPLC-UV detection
method was used. We have used this HPLC method with modifica-
tion to measure squalene in mouse plasma and found that squalene
level in plasma peaked 3.5 hours after i.p. injection [48]. Here, we
used the HPLC method to measure squalene level in BM at 3, 24,
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and 120 hours after a bolus dose of squalene-Intralipid (100 mg/kg)
injection. Briefly, after squalene injection, at an appropriate time in-
terval, blood was collected by intracardiac route and then animals
were killed to obtain BM. Subsequently, squalene was extracted from
plasma, BM, and SK-N-BE(2) tumor xenografts using the hexane-
based extraction method as described (details are given in the Sup-
plementary Methods section) [47,48]. A Shimadzu HPLC system
(Shimadzu Corporation; Kyoto, Japan) was used. Separation of squa-
lene was achieved within 6 minutes on a 15-cm reversed-phase C8 an-
alytical column with a particle size of 5 μm using a methanol mobile
phase [47,48]. Squalene level was expressed as micrograms per milli-
liter for plasma and micrograms per gram for BM and xenograft tissues
(Supplementary Methods).
Statistical Analysis
Measurements of colony growth of both BM cells and tumor cells
were normalized to the percentage of the control and analyzed by
one-way ANOVA. The data are presented as mean ± SD. The statis-
tical calculations were performed with GraphPad Prism 4.0 (Hearne
Scientific Software, Chicago, IL). A value of P ≤ .05 was considered
statistically significant.
Results
Squalene Exerts Protection Against Platinum-Induced
Weight Loss
The timing and dose of a cytoprotectant are important factors to
obtain effective cytoprotection [23]. It is therefore important to
know the pharmacokinetic profile of a cytoprotective agent before
undertaking the in vivo experiments. We have used a modified
HPLC method [47,48] to measure squalene level in mouse plasma.
We found that 3 hours after i.p. injection of a single-bolus 100-mg/kg
squalene dose, BM squalene levels reached 25 μg/g per milliliter
(Figure 1A; P = .002). This BM squalene level is above the required
dose of squalene for BM cytoprotection [13]. Furthermore, we found
that the BM squalene level remains above baseline level even at
24 hours and 5 days after the injection of squalene (Figure 1A; P =
.0048 and P = .0329, respectively). We also measured the squalene
level in the SK-N-BE(2)–derived xenografts after i.p. injection of
squalene and found that squalene level increased significantly in the
xenograft tissue. However, 24 hours after injection, the squalene level
did not remain significantly higher than the baseline level (Figure 1A;
P = .1145). Furthermore, the baseline squalene level dropped by
34% (P = .277). Although the differences between these data are
Figure 1. Injection of dietary squalene increases tissue level of squalene and reduces platinum-induced weight loss. (A) Histogram
shows the level of squalene in BM and plasma of BALB/C nude mice after injection of 100 mg/kg squalene-Intralipid i.p. injection. Squa-
lene level significantly increased in plasma, BM, and xenograft tissues 3 hours after injection. Note that BM squalene level remained
significantly higher than baseline level 24 hours after the injection. (B) (i) Histogram showing >10% weight loss after cisplatin (12 and
15 mg/kg) and carboplatin (100 mg/kg). Squalene (100 mg/kg) administration did not reduce weight. (ii) Squalene significantly reduced
cisplatin and carboplatin-induced weight loss. *P < .01, **P < .01, ***P < .0001. #P = .02.
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not significant, it may be suggestive of the rapid metabolism of squa-
lene in the xenograft tissue.
We then screened for the effect of a single dose of cisplatin or car-
boplatin on weight loss. Groups of mice (n = 8) were injected i.p.
with 10 to 15 mg/kg cisplatin or 100 to 120 mg/kg carboplatin, and
weights were measured daily. The 12- and 15-mg/kg cisplatin groups
and 120-mg/kg carboplatin group showed more than 10% weight loss
by day 5, whereas the 10-mg/kg cisplatin and 100-mg/kg carboplatin
groups showed less than 10% weight loss by day 5 (Figure 1B). To
investigate squalene-induced cytoprotection, drugs were injected
3 hours after the i.p. injection of squalene to SK-N-BE(2) xenograft–
bearing nude mice. Using this experimental design, we first demon-
strate that squalene treatment significantly reduced both cisplatin
(12 mg/kg)– and carboplatin (120 mg/kg)–induced weight loss
(Figure 1B), thus suggesting that the timing and dose of squalene injec-
tion was appropriate to investigate the potential cytoprotective activity
of squalene against platinum-induced BM toxicity.
Squalene Protects Against Platinum-Induced CFUs Toxicity
Initially, we investigated the drug-induced toxicity to CFUs. We
found that the 12- and 15-mg/kg cisplatin doses significantly reduced
CFUs number (Figure 2A; P < .05). We also measured the white
blood cell (WBC) count, which did not show significant changes
at the 12- and 15-mg/kg doses (data not shown). Conversely, carbo-
platin at a 120 mg/kg dose produced significant CFUs toxicity (Fig-
ure 2A) and a decrease in white blood count (data not shown). Earlier,
we found that cisplatin treatment significantly reduces large CFU–
granulocyte macrophage (CFU-GM) colonies in vitro, whereas con-
comitant treatment with squalene protects the large colonies [13].
Here, we found an equivalent significant protection of large-size CFU-
GM colonies (Figure 2B). Similar squalene-induced protection of
large CFU-GM was observed in the carboplatin-treated group (data
not shown).
Squalene Protects Against Platinum-Induced CFU-F Toxicity
Bone marrow microenvironment maintains a pool of mesenchymal
stem cells (MSCs) [49]. In vitro cultures established from single-cell
suspensions of mouse BM generate colonies of adherent marrow
stromal cells, each derived from a single precursor cell (CFU-F) having
characteristics of MSCs [50]. Mesenchymal stem cell can differen-
tiate into bone, fat, and cartilage and express Oct-4, a stemness gene
involved in embryonic stem cell self-renewal [49]. To establish the
CFU-F assay and characterize MSCs, BM cells were collected and
Figure 2. Squalene-induced protection against platinum-induced CFUs toxicity. (A) Histogram showing percent decrease in CFUs after
cisplatin and carboplatin treatment. Squalene treatment reversed the decrease in CFUs. Control CFUs colony number was 78.2 ± 8 per
1 × 105 LD-BM cells. (B) Two-week-old CFU-GM colony assay showing the predominance of large-size colonies in squalene- versus
cisplatin-treated groups (phase-contrast microscopy, ×10). To the right, the histogram shows the quantification of large colonies in
squalene versus cisplatin treatment group. Data were converted to percent control of mean value, and comparison was between the
platinum alone versus platinum + squalene treatment groups. *P < .01, ***P < .0001.
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grown in special mesenchymal culture medium and colonies were
enumerated as described previously [43,50]. When we grew these
colonies in the mesenchymal culture medium (detailed in the Ma-
terials and Methods section) and subjected to MSC characterization,
they expressedOct-4 and differentiated along osteogenic and lipogenic
lineages (Figure 3, A–C ). Cisplatin treatment led to dramatic changes
in the morphology of CFU-F colonies where normal-appearing
CFU-F cells were replaced by flat cells having prominent nucleoli
(Figure 3D). Similar morphologic changes were observed in carbo-
platin treatment group (data not shown). The morphologic changes
Figure 3. Squalene reduces platinum-induced MSC toxicity. (A, B, and C) Culture and characterization of murine MSCs, which were
grown in CFU-F colonies, express Oct-4 and differentiate to osteogenic and lipogenic lineages. (D) A murine MSC colony (CFU-F) show-
ing significant reduction of cellular content after cisplatin treatment. Addition of squalene recovered the cellularity of CFU-Fs. (E)
Histogram showing percentage decrease in CFU-F colonies after cisplatin treatment. Squalene treatment reversed the CFU-F decrease.
We found 16.6 ± 6 CFU-F colonies per 1 × 106 BM cells. Data were converted to percent control of mean value, and comparison was
between the platinum alone versus platinum + squalene treatment groups. *P < .01, ***P < .0001.
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were associated with a significant reduction in the number of CFU-F
colonies. The 12-mg/kg cisplatin dose induced CFU-F toxicity by
38% (P = .037), which was completely reversed by squalene (Fig-
ure 3E ). The 15-mg/kg cisplatin dose reduced CFU-F number by
65% (P = .006); squalene treatment reversed the loss of CFU-F by
45% (P < .0001). The 120-mg/kg carboplatin dose reduced CFU-F
number by 80% (P < .0001) and the addition of squalene reversed
the CFU-F loss by 32% (P = .0382; Figure 3E ).
Squalene Does Not Protect Tumor Against Platinum-Induced
Short-term (5 Days) Toxicity
Above results show that squalene exerted significant protection
against platinum-induced BM toxicity in a mice model of SK-N-BE
(2) xenograft growth. When the cisplatin-treated xenografts were in-
vestigated for the toxicity on the fifth day of treatment, the 15-mg/kg
cisplatin group demonstrated a significant reduction in tumor weight
(30%; P = .042) and clonogenic activity (63.5%; P = .0147). Cisplatin
+ squalene treatment reduced the tumor weight by 37% (P = .048) and
clonogenic activity by 64.7% (P = .078; Figure W1) suggesting that
combination treatment of squalene did not protect the tumor growth
from cisplatin-induced toxicity. We found similar results with xeno-
graft from H-146 (a small cell lung cancer cell line) and D-283 (a
medulloblastoma cell line), where cisplatin treatment significantly
reduced clonogenic growth, whereas squalene treatment had no effect
on cisplatin-induced antitumor activity (Figure W1).
Squalene Protects BM Against Long-term Platinum Toxicity
Without Protecting Tumor Growth
Considering that platinum drug may exert cumulative toxicity
[13], we tested squalene’s protective activity against the long-term
platinum toxicity in an SK-N-BE(2) xenograft model. In this model,
xenograft bearing mice were treated with cisplatin 10 mg/kg once
weekly for two consecutive weeks (treatment started at the fifth week
when the tumor size reached 0.2-0.25 cm3; n = 4). The 12-mg/kg
dose was not used because of the high mortality in mice within the
first 2 weeks after injection (data not shown). Carboplatin 100 mg/kg
once weekly for two consecutive weeks was used instead of 120 mg/kg
for the same reason. Squalene was injected 3 hours before the injection
of platinum drugs. At the end of 3 weeks after the last dose of drug
(i.e., at the ninth week after tumor inoculation), the animals were
killed, and BM was collected. We found that cisplatin treated mice
became weak, dehydrated, and lost 12.6% body weight (Figure 4A;
Figure 4. Squalene reduces platinum-induced long-term weight loss and BM toxicity. Histograms showing that squalene treatment
reverses platinum-induced (A) body weight loss, (B) CFUs toxicity, and (C) CFU-F toxicity. Note that the cisplatin treated group received
drugs for two consecutive weeks, whereas the carboplatin group received drugs for three consecutive weeks. Body weight was taken
and BM cell was harvested at the end of ninth week after the inoculation of tumor cells. Squalene was administered 3 hours before
each dose of platinum injection. Control CFUs: 82.2 ± 8.6 per 1 × 105 LD-BM cells. Control CFU-F: 17.8 ± 7.2 per 1 × 106 BM cells.
Data were converted to percent control of mean value, and comparison was between the platinum alone versus platinum + squalene
treatment groups. **P < .001, **P < .0001.
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P = .0253; n = 6), whereas mice receiving cisplatin + squalene appeared
active/alert and showed significant protection against weight loss com-
pared with the cisplatin-treated group (Figure 4A; P = .0323; n = 4). In
addition, the skin of cisplatin-treated mice exhibited keratin plaques
and appeared dry and wrinkled, whereas squalene-treated mice showed
almost no keratin plaques and appeared normal. Furthermore, the
cisplatin-treated group showed a 30% reduction in the number of
CFU colonies (P = .002) and a 46% reduction of CFU-F colonies
(P = .006), whereas the squalene + cisplatin–treated mice showed com-
plete recovery of both CFU and CFU-F colonies (Figure 4, B and C ).
We then investigated the effect of 100 mg/kg carboplatin once
weekly for 2 weeks and found that this dose regimen did not sig-
nificantly reduce mice body weight, whereas an additional dose
(100 mg/kg once weekly for three consecutive weeks) led to signifi-
cant body weight loss (Figure 4A), external signs of toxicity such as
dry and wrinkled skin, and a significant reduction of both CFUs
(50%; P = .0001) and CFU-F (70%; P = .0036). Addition of squa-
lene showed a dramatic recovery of both CFUs and CFU-F colonies
(Figure 4, B and C ).
Squalene Does Not Protect Tumors Growth Against the
Long-term Platinum-Induced Toxicity
Mice bearing SK-N-BE(2) (0.2-0.25 cm3; n = 4) were treated with
squalene (100 mg/kg) once weekly for two consecutive weeks (fifth
and sixth weeks after tumor cell inoculation) and were allowed to
grow until they reached 2 cm3 in size. Squalene treatment did not af-
fect the xenograft growth significantly (Figure 5A). Cisplatin treat-
ment initially reduced SK-N-BE(2) xenograft size significantly (P =
.024) at the seventh week and then regrew (repopulation) at the end
of the ninth week (Figure 5A). Carboplatin treatment for the 3-week
dose regimen showed similar results of repopulation (data not shown).
We recently found that SK-N-BE(2) tumor cell line contain a subpop-
ulation of stem cell–like cells resistant to cisplatin and other chemo-
therapeutic agents [51]. To test the selective cytoprotective activity of
squalene, it is important that the xenograft shows response to drug
treatment. We found that cisplatin treatment significantly reduced the
clonogenic activity ofH-146 andD-283 cells (FigureW1). Considering
that methylcellulose-based clonogenic assay measure the clonogenic
activity of tumor stem cell fractions [52,53], our data suggest that
Figure 5. Squalene does not protect against platinum-induced toxicity to tumor growth. (A) Effect of squalene on cisplatin-induced
reduction of SK-N-BE(2) xenograft growth. Treatment started when the tumor volume was 0.2 to 0.5 cm3 in size (second week after
tumor inoculation), and tumors were harvested at the end of the ninth week. (B) Significant reduction of D-283 xenograft volume after
cisplatin treatment. Note that squalene treatment increased the cisplatin toxicity. Treatment was achieved as explained above. (C) Sig-
nificant reduction of SH-SY5Y tumor weight after cisplatin (once weekly for 2 weeks) and carboplatin (once weekly for 3 weeks) treat-
ment with and without squalene. Note the significant increase in toxicity in the squalene + cisplatin–treated group. Treatment started
when the tumor volume was 0.05 to 0.1 cm3 in size (second week after tumor inoculation), and tumors were harvested at the end of the
ninth week when the control tumor reached >2 cm3 in size. *P < .05, **P < .001, ***P < .0001.
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cisplatin treatment may target the tumor stem cell fraction in these cell
lines. We then investigated the effect of cisplatin on the growth of
H-146 and D-283 xenografts and found that cisplatin treatment sig-
nificantly reduced the growth of D-283 (P < .01); squalene treatment
increased the cisplatin-induced toxicity, although it was not significant
(Figure 5B; P = .074). Although cisplatin showed significant toxic-
ity in the H-146 xenograft growth, the tumor grew rapidly 4 weeks
after the cessation of treatment. Squalene treatment did not effect the
growth behavior of the xenograft growth after cisplatin treatment
(data not shown) suggesting that the H-146 cell line may not be ap-
propriate to investigate the potential protective activity of squalene
against platinum-induced tumor growth. We subsequently used a neu-
roblastoma cell line SH-SY5Y, which is highly sensitive to platinum
treatment in vitro (unpublished data). Earlier, we found that squalene
did not protect SH-SY5Y cell line from several chemotherapeutic
agents including cisplatin and carboplatin in vitro [54]. We developed
a new model of in vivo xenograft toxicity, where mice were treated
with cisplatin or carboplatin when the tumor size reached 0.05 cm3
in size (the second week of inoculation) instead of allowing the tumor
to reach 0.2 to 0.25 cm3 in size before starting the treatment. For the
cisplatin group, treatment was administered for two consecutive weeks
(the long-term protection regimen for cisplatin; Figure 4) and for three
consecutive weeks for the carboplatin group (the long-term protection
regimen for carboplatin; Figure 4). When the control (untreated group)
reached 2 cm3 in size, all the mice including the treated group were
killed, tumor is removed and weighted. The results obtained from this
protocol revealed that cisplatin treatment group showed significant re-
duction in tumor growth (Figure 5C ; P = .0024). Most importantly,
squalene treatment potentiated the toxicity of cisplatin against SH-
SY5Y xenograft growth (Figure 5C ; P = .049). In the carboplatin treat-
ment group, significant reduction of tumor volume was observed with
the average tumor reaching a size of only 0.2 cm3 compared to >2 cm3 in
size of the untreated tumors suggesting significant toxicity. Squalene
treatment did not exert any significant influence against the antitumor
activity of carboplatin (Figure 5C).
Squalene Treatment Selectively Modulates Cisplatin-Induced
Reduction of Antioxidant Status in BM Versus Tumor Cells
Earlier, we proposed that the mechanism of squalene-mediated pro-
tection of BM cells may involve modulation of the cellular antioxidant
system including GSH [13]. Here, we investigated the potential mech-
anism of squalene-induced cytoprotection using cisplatin-induced BM
cell toxicity as a model.
Cisplatin treatment has been found to increase the generation of
oxygen free radicals, such as hydrogen peroxide, superoxide anions,
hydroxyl radicals, and nitric oxide in kidney and liver cells of rat and
Figure 6. Squalene reverses cisplatin-induced changes in ROS and GSH levels. (A) Significant up-regulation of ROS production in SK-N-
BE(2) and BM cells in vitro. Addition of squalene did not change the ROS level in tumor cells, whereas it reduced the ROS level in BM
cells significantly. Note that the basal level of ROS is higher in the tumor cells than in BM cells. (B) Cisplatin treatment significantly
decreased GSH level in LD-BM cells, whereas addition of squalene increased BM cell GSH levels significantly compared to cisplatin
group in vitro. (C) In vivo data showing similar results as in vitro, where GSH level was restored in LD-BM cells by squalene treatment,
whereas tumor GSH level remained unaffected. *P < .05, #P < .01, **P < .001.
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mouse [55–57]. Cisplatin reacts with intracellular GSH to form a
GS-platinum complex, which reduces the cellular GSH level signif-
icantly [58]. Miyajima et al. [59] showed that cisplatin treatment in-
creases ROS levels as detected by DCFH-DA assay and reduces GSH
levels in bladder cancer cells. Martins et al. [10] showed that high-
dose cisplatin led to increased ROS production and GSH depletion
in Wistar rats. However, the effect of cisplatin on ROS production
and antioxidant status in BM progenitor cells has not been studied.
Earlier, we found that 2-μM cisplatin treatment of human LD-BM
cells in vitro led to apoptosis, which can be rescued by treating with
25 μM squalene [13]. Here, we investigated the status of ROS and
GSH levels in the LD-BM cells after 2-μM cisplatin treatment
in vitro for 24 hours and 15-mg/kg cisplatin treatment in vivo for
5 days. When LD-BM cells were treated with 2 μM cisplatin in vitro,
ROS level increased (P = .0024) and GSH level decreased. Squalene
treatment significantly reduced ROS levels (P = .026) and increased
GSH level (P = .041; Figure 6, A and B). The in vivo measurement of
GSH supported the in vitro result; GSH level was reduced by more
than twofold (P = .006), which was reversed by squalene treatment
(P = .012; Figure 6C ).
We also investigated the effect of squalene on modulating ROS
and GSH levels in the tumor cells taking SK-N-BE(2) tumor cell as
a model cell line. SK-N-BE(2) cells were treated with 2 μM cisplatin
in vitro for 24 hours with and without squalene treatment, and the
ROS and GSH levels were measured. The ROS level increased sig-
nificantly (P = .036) and GSH level decreased marginally (P = .11)
after cisplatin treatment. Squalene treatment did not change the sta-
tus of ROS and GSH significantly (Figure 6, A and B). Interestingly,
the basal level of ROS was significantly higher in the SK-N-BE(2)
cells compared to BM cells (P = .0503; Figure 6A).
Cisplatin treatment has been reported to reduce antioxidant en-
zymes SOD, GST, and GSPx activities in liver and kidney leading
to toxicity [60]. However, SOD levels in lung and heart remain un-
changed after cisplatin treatment [60]. Here, we found that cisplatin
treatment increased SOD activity by 93% (P = .007) and reduced
GSPx and GST activity by 32% (P = .0502) and 49% (P = .0302),
respectively (Figure 7, A–C ). Squalene treatment increased the GSPx
and GST activities significantly (Figure 7, A and B; P < .02) and re-
versed cisplatin-induced SOD activity (Figure 7C ; P = .005). We also
measured the activities of the antioxidant enzymes SOD, GSPx, and
GST in the SK-N-BE(2) xenograft derived tissues and did not find
significant changes after cisplatin and/or squalene treatment (Figure 7,
A–C ).
Discussion
Platinum drugs are widely used in chemotherapy treatment against
cancer. Cisplatin and carboplatin are known to induce myelosup-
pression, nephropathy, neuropathy, and gastrointestinal dysfunction
Figure 7. Effect of squalene on the cisplatin-induced modulation of antioxidant enzyme activities. Cisplatin treatment showed signifi-
cantly reduced activity of (A) GST and (B) GSPx in the BM cells, whereas (C) SOD activity increased. Such changes were not observed in
the SK-N-BE(2) xenograft. Addition of squalene increased GSPx/GST and reversed SOD activity toward normal (untreated group). Squa-
lene treatment did not modulate SOD, GST, and GSPx levels in the tumor cells. After 5 days of treatment with cisplatin, mice were killed,
and SOD/GSPx/GST activities were measured in BM cells and in SK-N-BE(2). *P < .05, **P < .001. #P < .02.
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[10,58–60]. However, the potential effect of cisplatin and carbopla-
tin against BM progenitor cells including the MSC fraction is not
known. Here, we show that acute high-dose cisplatin/carboplatin
may target the BM progenitor population including the hemato-
poietic and mesenchymal progenitor fractions. Furthermore, we have
shown that squalene, a nontoxic antioxidant found in the diet, and
particularly high in olive oil, exerts in vivo protective effect against
cisplatin and carboplatin–induced BM toxicity without protecting
tumor growth. We also report squalene-mediated differential modu-
lation of the antioxidant system in BM compared with tumor cells
after cisplatin treatment.
We used the LD-BM fraction of BALB/c nude mice as representa-
tive of primitive BM stem cell fraction. The LD-BM fraction is ob-
tained by Percoll gradient separation and has been consistently
shown to be enriched in both short-term and long-term hematopoietic
stem cells [61,62]. Earlier, we had shown that cisplatin treatment tar-
gets the CFU-GM and CFU–granulocyte-erythroid-macrophage-
megakaryocyte fraction of LD-BM cells in vitro [13]. Here, we found
that cisplatin may target the LD-BM–derived CFUs in vivo. Further-
more, cisplatin also exerts toxicity against the CFU-F fraction, which
is enriched in BM-derived MSCs [50]. Such toxicity against the BM-
derived stem cells has tremendous clinical implications particularly
in the pediatric population where chemotherapeutic drug toxicities
may have long-term implications on growth and development. Inter-
estingly, we did not observe a significant drop of WBC count after
cisplatin treatment, whereas carboplatin treatment reduced WBC
count, which was reversed by squalene treatment (data not shown).
The mechanism of squalene-mediated protection of hematopoietic
and mesenchymal progenitor cells from the platinum-induced toxicity
is not known. Considering that dietary antioxidant scavenges free rad-
icals including hydroperoxides [63] and that the platinum-induced
tissue toxicity may be related to the generation of ROS [16], it may
be presumed that squalene may reduce platinum-induced oxidative
stress on the BM progenitors. Cisplatin treatment has been found to
increase the generation of oxygen free radicals, such as hydrogen per-
oxide, superoxide anions, hydroxyl radicals, and nitric oxide in kidney
and liver cells of rat and mouse [55–57]. Reports obtained from our
study indicate that cisplatin treatment increases ROS level in the BM
cells as measured by the DCFH-DA assay. The oxidation of DCFH to
the fluorescent compound 2′-9′-dichlorofluorescein is modulated
mainly by hydroperoxides including H2O2 [64] and peroxynitrite
[65]. Due to the rapid rate of the dismutation of superoxide anions
to H2O2, the endogenous H2O2 level may be used as an indirect mea-
sure of superoxide anion. Our findings that cisplatin treatment in-
creases 2′-9′-dichlorofluorescein fluorescence level in BM cells may
reflect cellular oxidant stress because of the increased generation of
various free radicals including H2O2 and superoxide anions. Several re-
ports suggest that increased ROS generation after cisplatin treatment
reduces GSH level and GSPx/GST activity in kidney and liver tissues
[55–57,66,67]. Additionally, free radicals may inactivate GSPx through
the modification of a cysteine-like essential residues on GSPx [68].
We found that cisplatin treatment significantly reduces GSPx and
GST activity in BM cells, whereas SOD level was significantly in-
creased in BM cells. Previous reports suggest significant decrease of
SOD in liver and kidney tissues after cisplatin treatment [55,56,66].
We also found that SOD level decreases in a hepatic cell line WRL-
68 after cisplatin (2 μM for 24 hours) treatment [69]. Conversely,
Sadzuka et al. [60] found that cisplatin treatment did not decrease
SOD level in lung and heart, whereas significant reduction in SOD
activity was detected in liver tissues suggesting that cisplatin-induced
reduction of SOD may be tissue- and cell type–specific. Cetin et al.
[70] investigated the level of SOD in patients undergoing high-dose
chemotherapy including cisplatin therapy and found that SOD ac-
tivity was increased significantly in days 3 and 6 after the high-dose
chemotherapy. Recent report suggest that MnSOD activity is in-
creased by very high dose cisplatin treatment (500 μM cisplatin for
a 1-hour treatment) in a renal cell line, LLC-PK1 [71]. We measured
the total SOD activity using Cayman SOD assay kit that measures all
three types of SOD (Cu/Zn-, Mn-, and FeSOD). Whether increased
SOD activity in the BM cells is due to the increase inMnSOD activity
requires further investigation.
Both SOD and GSPx modulate the conversion of highly toxic su-
peroxide anions to molecular oxygen and water in a two-step enzy-
matic process: first, the dismutation of superoxide anion to hydrogen
peroxide by SOD; second, the conversion of hydrogen peroxide to
molecular oxygen and water by GSPx and/or catalase. Therefore, the
balance between the first and second steps of enzyme activity may
be critical to maintain cellular antioxidant defense. Overabundant
SOD activity and diminished GSPx activity may lead to a net in-
crease in hydrogen peroxide intermediates. The resulting hydroxyper-
oxides (OH·) are even more harmful than superoxide anions [72,73]
and may be related to several disease pathologies [73–75]. Our data
suggest that after cisplatin treatment in vivo, the SOD activity in
BM cells increased whereas GSPx activity decreased. The changes in
SOD and GSPx activity was associated with reduced GSH and GST
levels and a significant decrease in both hematopoietic and MSC
colony growth.
Squalene increased the GSPx and GST activity and reduced the
cisplatin-mediated increase of SOD activity in BM cells. It is possible
that squalene reverses the cisplatin-mediated induction of SOD,
thus restoring the balance between SOD and GSPx activity. Mishima
et al. [71] found thatN -acetyl cysteine (NAC) and cAMP reverses the
cisplatin-induced MnSOD activity in LLC-PK1 cell line leading to
protection from cisplatin-induced cell death. Considering that squa-
lene treatment reversed the cisplatin-induced SOD activity in BM
cells, it will be important to find out whether MnSOD activity is re-
versed by squalene. Earlier, Sabeena Farvin et al. [76] reported that
squalene restored the levels of several antioxidant enzymes including
GSPx, SOD, and GST in rat myocardium after isoproterenol-induced
myocardial infarction. However, it is not known whether MnSOD
or Cu/ZnSODwas increased after squalene treatment. Future studies
of squalene-induced SOD modulation should include measuring the
activity of all the three major types of SOD (Cu/ZnSOD, MnSOD,
and extracellular SOD).
The mechanism of squalene-mediated modulation of SOD level
in the LD-BM cells during oxidative stress is not known. Cisplatin
treatment may modulate SOD level by activating p38/MAPK sig-
naling pathway [71]. Additionally, Nrf-2 (NF-E2–related factor 2),
a transcription factor associated with the restoration of antioxidant
system after chemical stress [77], has been found to be activated after
cisplatin treatment [78]. Considering that cisplatin may also modu-
late SOD level by activating Nrf-2 signaling [78], squalene may sup-
press cisplatin-induced Nrf-2 activity. Therefore, future investigation
should take in consideration of understanding the potential link be-
tween squalene and the stress signaling pathways including p38/
MAPK and Nrf-2. Such investigation may further our understand-
ing of the role of dietary squalene in the regulation of cellular anti-
oxidant balance.
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It is crucial that cytoprotective and rescue agents do not protect
tumor cells from the toxicity of chemotherapeutic agents. Our study
indicates that squalene did not exert a protective effect on tumor cell
growth in vivo. We have examined the possible squalene-induced pro-
tection of in vivo tumor growth against cisplatin and carboplatin–
induced toxicity and found that squalene did not exert a great influence
on the tumor growth/toxicity. These data support our previous in vitro
data that showed that squalene did not exert protection of neuro-
blastoma cell lines against platinum-induced toxicity [13]. The mech-
anism of such selective protection of BM cells versus tumor cell growth
by squalene against platinum-induced toxicity is not known. We
found that squalene treatment decreased ROS level and increased
the GSH level in the BM cells but not in the SK-N-BE(2) tumor cells.
It is possible that squalene selectively increases GSH levels in BM
versus tumor cells, a phenomenon we earlier described as the “GSH-
paradox” [13,79]. We found that OTZ (L-2-oxothiazolidine-4-
carboxylate), a GSH prodrug, is able to selectively decrease tumor
GSH levels. It was observed that tumor GSH levels are depleted
(chemopotentiation) whereas normal tissue GSH levels are elevated
(chemoprotection). This phenomenon of a “GSH paradox” suggests
that GSH-enhancing agentsmay be used to differentially protect normal
versus tumor tissues [79]. The selective increase of antioxidant system
in the BM cells by an antioxidant may be related to the different regu-
lation of antioxidant system in normal versus tumor cells. Genomic in-
stability is a hallmark of tumor cells, and tumor cells may be under a
continued environment of oxidative stress, where antioxidant may act
as a pro-oxidant [80–82]. Schwartz [83] suggested that dietary antiox-
idants may act as and antioxidant to normal cells and as a pro-oxidant to
cancer cells. The pro-oxidant activity of an antioxidant may be the rea-
son for the antitumor activity of many antioxidants including NAC, ly-
copene, squalene, and vitamin E [16,28,29, 81,84,85]. Here, we found
that the basal level of ROS was significantly higher in the SK-N-BE(2)
tumor cells than the LD-BM cells. Whether such a different cellular
microenvironment of tumor cells rendered the antioxidant activity of
squalene ineffective in the tumor cells needs further investigation.
Another possibility for the selective protection of squalene in BM
versus tumor cells may be related to the difference in the cellular up-
take or the status of the mevalonate pathway, the latter being the cho-
lesterol synthesis pathway in cells. We have measured tumor squalene
and found that, at least in the tumor level, uptake of squalene does not
differ. Cancer cells may synthesize its own cholesterol, and therefore,
dietary squalene may end up being used up for cholesterol synthesis.
This possibility is supported by our findings that squalene level was
higher in the tumor xenograft than in BM cells. Furthermore, addition
of squalene increased the tumor squalene level by several folds. How-
ever, within the next 5 days, the squalene level decreased below
the baseline level. It is possible that exogenous squalene may inhibit
the cellular synthesis in the cancer cells. This possibility is supported
by several preliminary findings that squalene may inhibit the enzyme
squalene synthase or HMG-CoA reductase.
Nakagawa et al. [37] found that dietary squalene potentiated
the toxicity of several chemotherapeutic agents in murine sarcoma.
Earlier, we found that squalene treatment increased the etoposide-
induced toxicity of SK-N-SH neuroblastoma cell line in vitro [13].
Dietary squalene may also have direct antitumor activity, which may
be related to the inhibition of the HMG-CoA reductase enzyme, the
rate-limiting enzyme of the cholesterol metabolism [29,86]. The me-
valonate pathway is highly active in tumor cells including mitochon-
dria, and several byproducts of the metabolism are required for protein
isoprenylation. Inhibition of the mevalonate pathway by the inhibitor
of squalene synthase has been found to reduce tumor growth and po-
tentiate the toxicity of doxorubicin [87,88]. Here, we found that SK-
N-BE(2) tumor tissue contains a high level of endogenous squalene,
which may reflect the high activity of the squalene synthesis pathway
in the tumor cells. We also found that addition of exogenous squa-
lene reduced the baseline squalene level in the tumor cells by 34%
(P = .277). The administration of squalene to SH-SY5Y xenograft–
bearing mice potentiated cisplatin-induced tumor growth reduction.
Therefore, it is necessary to investigate whether dietary squalene
may exert feedback inhibition to the squalene synthesis pathway in
the tumor tissue.
There is an urgent need for the clinical development of safe and
nontoxic cytoprotective agents for the adequate management of the
adverse effects of cancer chemotherapy [24]. Amifostine represents
one of the most well studied and common cytoprotectants in clinical
practice. However, intravenous administration of amifostine in a
phase III clinical trial resulted in toxicities in 41% of head and neck
cancer patients, including hypotension, hypocalcemia, nausea, vomit-
ing, and allergy, and necessitated withdrawal of treatment [89]. The
hypotensive property of amifostine precludes treatment of patients
on hypertensive medication and requires administration of a large
volume of saline administered before amifostine to prevent a major
drop in blood pressure [85]. Nonetheless, a substantial drop in blood
pressure may occur, leading to discontinuation of amifostine admin-
istration [85]. In addition, even subcutaneous injections of amifostine
have incited severe reactions including Stevens-Johnson syndrome,
erythemamultiforme, toxic epidermal necrolysis, and bullae [90]. Res-
cue agents such as CSFs are also used to ameliorate the toxic effects of
chemotherapy and radiotherapy. They primarily function by stimulat-
ing the BM to undergo hematopoietic expansion. Colony-stimulating
factor such as granulocyte CSF is administered 24 hours after the last
dose of chemotherapy or radiotherapy because CSFs administered in
conjunction with chemotherapy enhances BM toxicity by increasing
neutropenia and thrombocytopenia [91]. Here, we have shown that
squalene administered in conjunction with cisplatin and carboplatin
protects BM progenitors. Furthermore, squalene treatment reduced
cisplatin-induced body weight loss in both short-term (5 days) and
long-term (4 weeks) treatment schedules without protecting tumor
growth. In a phase I trial, adult males were given 860 mg of squa-
lene daily for 20 weeks to study the cholesterol-lowering effect
of squalene. Squalene was found to be safe and tolerable at high
doses; of 26 patients studied, only 1 patient complained of diarrhea
[92]. Considering the nontoxic nature of dietary squalene, the po-
tential clinical assessment of this agent in the pediatric population is
warranted. Squalene, being a nontoxic dietary antioxidant, may be
particularly beneficial in the pediatric population against platinum-
induced BM progenitor cell toxicity. Storm et al. [30] demonstrated
the protective effect of squalene against radiation-induced BM dam-
age. Hamilton et al. [93] found that Hjorth adjuvant (10% w/v
squalene in water) increased the survival and proliferation of murine
BM–derived cells. Whether squalene-induced protection of BM cells
also extends to toxicity related to other chemotherapeutic agents, such
as alkylating agents, requires further investigation. Further investiga-
tion of squalene cytoprotection against chemotherapeutic agents in-
cluding using orally administered dose is necessary for future clinical
trials in humans.
Although we found that squalene does not protect tumor cell
growth from the cisplatin-induced toxicity, it is unknown whether
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squalene may support the growth of a small subfraction of tumor
stem cells. We recently found that SK-N-BE(2) and H-146 cell lines
contain a small fraction of tumor stem cell–like cells having a very
high tumorigenic capacity [45], whereas the SK-N-BE(2)–derived
tumor side population cells are highly resistant to cisplatin treatment
[51]. Here, we found that although cisplatin treatment initially led
to shrinkage of the SK-N-BE(2) and H-146 (data not shown), the
tumor growth quickly regained suggesting the potential role of tu-
mor stem cell fraction in repopulation [94]. Squalene treatment did
not significantly affect this repopulation phase. Further investigation
is necessary to find out if squalene may reduce the repopulation of
tumor stem cell after chemotherapy.
Future work still remains to be done to extend the cytoprotec-
tive findings we have reported here. Firstly, it will be necessary to in-
vestigate whether squalene can also protect BM cells against chronic
platinum-induced toxicity including protection against nephro-
toxicity, hepatotoxicity, and ototoxicity. Secondly, the potential BM
protective effect of squalene against other frequently administered che-
motherapeutic agents such as cyclophosphamide should be explored.
In summary, we found that squalene exerts a cytoprotective effect
on BM and against platinum-induced BM toxicity in mice. Consider-
ing the nontoxic nature of dietary squalene, the potential use of this
agent for the pediatric population undergoing cancer treatments
should be considered.
Supplementary Methods
Animals
Eight- to ten-week-old female BALB/c/nude/nude mice were ob-
tained from Charles River Laboratories. All animal experimentation
was in accordance with the criteria of the Guide for the Care and
Use of Laboratory Animals prepared by the National Academy of
Sciences, Washington, DC. Protocols for animal experimentation
were approved by the Animal Safety Committee, Research Institute,
The Hospital for Sick Children, Toronto. The mice were accli-
matized 1 week before the planned experiments. They were fed
ad libitum and were housed in individual cages on a 12-hour light/
dark cycle. In the initial experiment, mice were dosed with cisplatin
(8-15 mg/kg, i.p.; n = 5 for each group). The control mice (n = 5)
received saline only. After 5 days of treatment, the mice were weighed
and then anesthetized, and blood was removed by intracardiac punc-
ture. The mice were then euthanized by cervical dislocation, and BM
was collected as described [1]. Blood was processed for total WBC
count using an automated analyzer in the clinical laboratory division
of The Hospital for Sick Children. Bone marrow specimens were
either processed for CFU and CFU-F assays as described below or
stored appropriately for the measurement of GSH, SOD, and GSPx
as described below. For the measurement of tissue squalene levels,
xenograft-bearing mice were divided into four groups (each group;
n = 4). Group 1 received normal saline. Groups 2 to 4 received squa-
lene 100 mg/kg, i.p. Mice from each group were euthanized at 0-, 4-,
24-, and 120-hour intervals. The animal blood, BM, and tumor
tissues were collected for the HPLC measurement of squalene (de-
scribed below). For the measurement of squalene-induced cytopro-
tection, mice were divided into groups (n = 6) receiving cisplatin
(12 or 15 mg/kg i.p.) with or without squalene (100 mg/kg of
squalene-Intralipid solution, i.p., 3 hours before the injection of cis-
platin) or NAC (10 mg/kg dissolved in normal saline i.p. 1 hour be-
fore the injection of cisplatin). The control group received Intralipid
solution only.
For themeasurement of long-term protection of squalene, a separate
protocol was used as described in the Materials and Methods section
in the main text.
Squalene Extraction and HPLC Measurement
Briefly, after squalene injection into mice, blood was collected,
animals were killed, and BMs and tumor tissues were collected.
Blood was collected in a microcentrifuge tube and centrifuged at
8000 rpm, and the serum was stored at −80°C. For squalene extrac-
tion, serum was thawed, mixed with propanol and hexane, and vor-
texed, and the clear top hexane layer was collected in a glass tube and
evaporated under a stream of liquid nitrogen. The dried residue was
reconstituted in 100 μl of methanol and subjected to HPLC quali-
fication. For measurement of tumors, 50 mg of tissue was first mixed
with 0.5 ml of water, homogenized, and kept at room temperature
for 5 to 10 minutes for the total lysis of cells. Subsequently, 0.5 ml of
propanol was added and homogenized again; then 0.5 ml of hexane
was added to the homogenized suspension, and the extraction pro-
cedure was completed as described previously. Squalene concentra-
tions in BM cells were measured by collecting the cells in PBS
solution and by storing them at −80°C. For the extraction, samples
were thawed and centrifuged, and the pellet was weighed. 0.1 ml of-
water was added, and the solution was incubated at room tempera-
ture for 5 to 10 minutes. Then, 0.1 ml of propanol was added per
10 mg of pellet, vortexed vigorously for next 5 minutes, 0.1 ml of
hexane was added and vortexed again as per the extraction procedure.
Squalene level was expressed as micrograms per milliliter for plasma
and micrograms per gram for BM and xenograft tissues.
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Figure W1. Squalene does not protect tumor against platinum-induced short-term (5 days) toxicity. (A) Significant reduction of SK-N-BE
(2) tumor weight after 15-mg/kg cisplatin treatment. Squalene treatment did not alter the cisplatin-induced reduction in tumor weight.
Treatment started when the tumor size was 0.2 to 0.25 cm3, and tumors were harvested on the fifth day of treatment. (B) Significant
reduction of cisplatin-treated SK-N-BE(2) xenograft–derived tumor cell clonogenic activity. (C and D) Significant reduction of cisplatin-
treated H-146 and D-283 xenografts–derived tumor cell clonogenic activity. Addition of squalene did not alter the cisplatin-induced col-
ony reduction. Tumor tissues were dissociated, and 2 × 103 cells were plated in 35-mm dishes as described and colony was counted
after 2 weeks. *P < .05.
